Sekisui Spectrolyse PAI-1, In-Vitro Diagnostic for Quantitative determination of Plasminogen Acti...
FDA Device Recall #Z-2431-2012 — Class II — August 28, 2012
Recall Summary
| Recall Number | Z-2431-2012 |
| Classification | Class II — Moderate risk |
| Date Initiated | August 28, 2012 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Sekisui Diagnostics Llc |
| Location | Stamford, CT |
| Product Type | Devices |
| Quantity | 699 kits |
Product Description
Sekisui Spectrolyse PAI-1, In-Vitro Diagnostic for Quantitative determination of Plasminogen Activator Inhibitor Type- 1 (PAI-1) activity in human plasma. Catalog Number: 101201 For the determination of Plasminogen Activator Inhibitor Type 1 (PAI-1) activity in human plasma. The test is for in Citro diagnostic use.
Reason for Recall
SPECTROLYSE PAI-1 activity assay producing lower than expected absorbance values with "0" standard. This will reduce the slope of the standard curve requiring the user to make more frequent sample dilutions.
Distribution Pattern
Nationwide distribution: USA including states of: FL, IN, IL, and WA.
Lot / Code Information
Lot Numbers: 120425 and 120601
Other Recalls from Sekisui Diagnostics Llc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-0015-2014 | Class II | Product Name: OSOM C. Difficile Toxin A/B Test ... | Sep 16, 2013 |
| Z-0463-2013 | Class II | Sekisui Diagnostics, Spectrolyse PAI-1 In-Vitro... | Oct 24, 2012 |
| Z-1902-2012 | Class II | MULTIGENT Acetaminophen for use with Architect/... | May 29, 2012 |
Frequently Asked Questions
Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.